-
Something wrong with this record ?
Nedostatečná reakce na intravitreální léčbu ranibizumabem u foveomakulární vitellioformní dystrofie s nástupem v dospělosti doprovázené choroidální neovaskularizací. Kazuistika
[Lack of Response to Intravitreal Ranibizumab Treatment in Adult Onset Foveomacular Vitelliform Dystrophy Complicated with Choroidal Neovascularization: A Case Report]
Mustafa Berhuni, Nesime Setge Tıskaoğlu, Cem Ozturkmen
Language Czech Country Czech Republic
Document type Case Reports
PubMed
38925903
DOI
10.31348/2024/21
Meditorial
- MeSH
- Vitelliform Macular Dystrophy * diagnostic imaging diagnosis drug therapy MeSH
- Antibodies, Monoclonal, Humanized administration & dosage pharmacology therapeutic use MeSH
- Angiogenesis Inhibitors administration & dosage pharmacology therapeutic use MeSH
- Intravitreal Injections MeSH
- Middle Aged MeSH
- Humans MeSH
- Choroidal Neovascularization diagnostic imaging drug therapy MeSH
- Ranibizumab administration & dosage therapeutic use MeSH
- Check Tag
- Middle Aged MeSH
- Humans MeSH
- Female MeSH
- Publication type
- Case Reports MeSH
Adult-onset foveomacular vitelliform dystrophy (AOFVD) is a rare disease characterized by accumulation of yellowish deposits in the macula. Rarely, it may be complicated by choroidal neovascularization (CNV). Cases with CNV may be confused with occult CNV in age-related macular degeneration. In our case, we will present the visual and anatomical results of a patient with AOVF-related CNV, in which we administered 3 doses of intravitreal ranibizumab (IVR). A 59-year-old female patient, who attended our clinic with the complaint of decreased vision in both eyes, was diagnosed with AOVF-related CNV in both eyes and was treated with 3 doses of IVR for 3 months. Despite the improvement in visual and anatomical functions 1 month after the first dose, vision decreased, and anatomical functions regressed to the pre-injection state in continued injections. IVR therapy is not an appropriate treatment option in the treatment of AOVF-associated CNV.
Lack of Response to Intravitreal Ranibizumab Treatment in Adult Onset Foveomacular Vitelliform Dystrophy Complicated with Choroidal Neovascularization: A Case Report
References provided by Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc25004997
- 003
- CZ-PrNML
- 005
- 20251010094400.0
- 007
- ta
- 008
- 250821s2025 xr cad f 000 0|cze||
- 009
- AR
- 024 7_
- $a 10.31348/2024/21 $2 doi
- 035 __
- $a (PubMed)38925903
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a cze $b eng
- 044 __
- $a xr
- 100 1_
- $a Berhuni, Mustafa $u Ersin Arslan Research and Education Hospital, Gaziantep, Turkey
- 245 10
- $a Nedostatečná reakce na intravitreální léčbu ranibizumabem u foveomakulární vitellioformní dystrofie s nástupem v dospělosti doprovázené choroidální neovaskularizací. Kazuistika / $c Mustafa Berhuni, Nesime Setge Tıskaoğlu, Cem Ozturkmen
- 246 31
- $a Lack of Response to Intravitreal Ranibizumab Treatment in Adult Onset Foveomacular Vitelliform Dystrophy Complicated with Choroidal Neovascularization: A Case Report
- 520 9_
- $a Adult-onset foveomacular vitelliform dystrophy (AOFVD) is a rare disease characterized by accumulation of yellowish deposits in the macula. Rarely, it may be complicated by choroidal neovascularization (CNV). Cases with CNV may be confused with occult CNV in age-related macular degeneration. In our case, we will present the visual and anatomical results of a patient with AOVF-related CNV, in which we administered 3 doses of intravitreal ranibizumab (IVR). A 59-year-old female patient, who attended our clinic with the complaint of decreased vision in both eyes, was diagnosed with AOVF-related CNV in both eyes and was treated with 3 doses of IVR for 3 months. Despite the improvement in visual and anatomical functions 1 month after the first dose, vision decreased, and anatomical functions regressed to the pre-injection state in continued injections. IVR therapy is not an appropriate treatment option in the treatment of AOVF-associated CNV.
- 650 07
- $a lidé $2 czmesh $7 D006801
- 650 07
- $a lidé středního věku $2 czmesh $7 D008875
- 650 07
- $a ženské pohlaví $2 czmesh $7 D005260
- 650 17
- $a Bestova nemoc $x diagnostické zobrazování $x diagnóza $x farmakoterapie $2 czmesh $7 D057826
- 650 07
- $a neovaskularizace choroidey $x diagnostické zobrazování $x farmakoterapie $2 czmesh $7 D020256
- 650 07
- $a ranibizumab $x aplikace a dávkování $x terapeutické užití $2 czmesh $7 D000069579
- 650 07
- $a humanizované monoklonální protilátky $x aplikace a dávkování $x farmakologie $x terapeutické užití $2 czmesh $7 D061067
- 650 07
- $a inhibitory angiogeneze $x aplikace a dávkování $x farmakologie $x terapeutické užití $2 czmesh $7 D020533
- 650 07
- $a injekce intravitreální $2 czmesh $7 D058449
- 655 _7
- $a kazuistiky $2 czmesh $7 D002363
- 700 1_
- $a Tıskaoğlu, Setge Nesime $u Ersin Arslan Research and Education Hospital, Gaziantep, Turkey
- 700 1_
- $a Ozturkmen, Cem $u Goznuru Eye Hospital, Gaziantep, Turkey
- 773 0_
- $w MED00010980 $t Česká a slovenská oftalmologie $x 1211-9059 $g Roč. 81, č. 1 (2025), s. 38-40
- 856 41
- $u https://www.prolekare.cz/casopisy/ceska-slovenska-oftalmologie/2025-1-2/lack-of-response-to-intravitreal-ranibizumab-treatment-in-adult-onset-foveomacular-vitelliform-dystrophy-complicated-with-choroidal-neovascularization-a-case-report-137279 $y Meditorial
- 910 __
- $a ABA008 $b A 202 $c 639 $y p $z 0
- 990 __
- $a 20250206 $b ABA008
- 991 __
- $a 20251010094346 $b ABA008
- 999 __
- $a ok $b bmc $g 2392115 $s 1242015
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2025 $b 81 $c 1 $d 38-40 $i 1211-9059 $m Česká a slovenská oftalmologie $x MED00010980 $y 137279
- LZP __
- $c NLK109 $d 20250926 $b NLK111 $a Meditorial-20250206
